Genome mining and genetic analysis of cypemycin biosynthesis reveal an unusual class of posttranslationally modified peptides.
Posttranslational modification of amino acids confers a range of structural features and activities on ribosomally synthesized peptides, many of which have potent antimicrobial or other biological activities. Cypemycin is an extensively modified linear peptide produced by Streptomyces sp. OH-4156 with potent in vitro activity against mouse leukemia cells. Cypemycin does not contain lanthionine bridges but exhibits some of the structural features of lantibiotics, notably dehydrated threonines (dehydrobutyrines) and a C-terminal S-[(Z)-2-aminovinyl]-D-cysteine. Consequently it was classified as a member of the lantibiotic family of posttranslationally modified peptides. Cypemycin also possesses two L-allo-isoleucine residues and an N-terminal N,N-dimethylalanine, both unique amino acid modifications. We identified and heterologously expressed the cypemycin biosynthetic gene cluster and performed a mutational analysis of each individual gene. We show that even the previously described modifications are carried out by unusual enzymes or via a modification pathway unrelated to lantibiotic biosynthesis. Bioinformatic analysis revealed the widespread occurrence of cypemycin-like gene clusters within the bacterial kingdom and in the Archaea. Cypemycin is the founding member of an unusual class of posttranslationally modified ribosomally synthesized peptides, the linaridins.
Claesen
Jan
J
Department of Molecular Microbiology, John Innes Centre, Norwich NR4 7UH, United Kingdom.
Bibb
Mervyn
M
D000595:Amino Acid Sequence; D000900:Anti-Bacterial Agents / Q000096:biosynthesis* / Q000737:chemistry; D001426:Bacterial Proteins / Q000737:chemistry / Q000378:metabolism*; D001430:Bacteriocins / Q000096:biosynthesis* / Q000737:chemistry; D016680:Genome, Bacterial; D008969:Molecular Sequence Data; D005810:Multigene Family; D009154:Mutation; D010455:Peptides / Q000737:chemistry / Q000378:metabolism; D011499:Protein Processing, Post-Translational; D013302:Streptomyces / Q000737:chemistry / Q000235:genetics* / Q000378:metabolism*
D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D001430:Bacteriocins; D010455:Peptides; C085033:cypemycin
J Biol Chem. 2000 Oct 13;275(41):31838-46
10922366
Mol Microbiol. 2004 Jul;53(2):433-43
15228525
J Mol Biol. 1983 Jun 5;166(4):557-80
6345791
Nat Chem Biol. 2010 Jan;6(1):9-18
20016494
J Pharmacol Toxicol Methods. 2010 Mar-Apr;61(2):210-8
20176117
Trends Biochem Sci. 2004 Jan;29(1):4-7
14729325
Methods Enzymol. 2009;458:559-74
19374998
Curr Pharm Des. 2002;8(9):815-33
11945173
Adv Appl Microbiol. 2004;54:107-28
15251278
Nat Prod Rep. 2009 Apr;26(4):537-59
19642421
Chem Rev. 2005 Feb;105(2):633-84
15700960
J Antibiot (Tokyo). 1993 Nov;46(11):1666-71
7802859
Biochemistry. 2005 Jun 21;44(24):8873-82
15952794
Mol Microbiol. 2009 Jun;72(5):1126-36
19400806
EMBO J. 2000 Dec 1;19(23):6299-310
11101502
Curr Drug Discov Technol. 2009 Mar;6(1):1-18
19275538
J Nat Prod. 2008 Jul;71(7):1193-6
18558743
Proc Natl Acad Sci U S A. 1991 Mar 15;88(6):2461-5
1826053
Nature. 2002 May 9;417(6885):141-7
12000953
Anal Chem. 1998 Dec 15;70(24):5150-8
9868912